Ketamine
Ketamine is a dissociative anesthetic and NMDA-glutamate-receptor antagonist. Beyond its long-standing use in anesthesia and pain control, sub-anesthetic doses act as a rapid-acting antidepressant — often relieving treatment-resistant depression and acute suicidal ideation within hours — by triggering a burst of glutamate signaling and synaptic plasticity (BDNF/mTOR). The S-enantiomer, esketamine, is an approved nasal spray. Ketamine is also misused recreationally ("Special K") for its dissociative "K-hole" effects, and chronic heavy use carries real harms.
Too much may be associated with
Dissociation, bladder/urinary damage, dependence, and memory problems.
Informational only — not medical advice.
Benefits
Rapid (hours, not weeks) antidepressant effect, including in treatment-resistant depression; reduces acute suicidal ideation; potent analgesic and anesthetic with a wide safety margin; promotes synaptic plasticity (BDNF/mTOR); emerging evidence in PTSD, anxiety, and substance-use disorders when given under medical supervision.
Risks
Dissociation, hallucinations, and confusion; abuse and dependence potential; chronic heavy use causes ketamine-induced cystitis (painful bladder/urinary-tract damage) and hepatobiliary problems; transient rises in blood pressure and heart rate; acute memory and cognitive impairment; risk of accidents while intoxicated. Benefits depend on controlled, supervised dosing.
Informational only — not medical advice.
Neurotransmitters
Related
- Anxiety Regulation (↑)(prelim)
- Emotional Regulation (↑)
- Neuroplasticity (↑)
- Addiction (↕)(prelim)
- Consciousness (↕)
- Fear Processing (↕)(prelim)
- LSD
- MDMA(HARMFUL)
- Psilocybin
- Reward Processing (↕)(prelim)
- Depression (↓)
- Memory (↓)
- Pain Perception (↓)
Books (3)
Research (22)
- All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants Freudenberg et al. (2025) Full text ↗ PubMed ↗
- Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions? Michaelides et al. (2025) PubMed ↗
- Interactions Between Anesthesia and Sleep: Optimizing Perioperative Care to Improve Sleep Quality and Surgical Recovery Outcomes Patel et al. (2025) Full text ↗ PubMed ↗
- Alcohol Withdrawal Meloy et al. (2025) Full text ↗ PubMed ↗
- Personalized use of ketamine and esketamine for treatment-resistant depression Zarate et al. (2024) PubMed ↗
- Glutamatergic Modulators for Major Depression from Theory to Clinical Use McIntyre et al. (2024) Full text ↗ PubMed ↗
- Ketamine: Mechanisms and Relevance to Treatment of Depression Kim et al. (2024) PubMed ↗
- Depression and the Glutamate/GABA-Glutamine Cycle Mamelak (2024) Full text ↗ PubMed ↗
- Psilocybin and Other Classic Psychedelics in Depression Nutt et al. (2024) Full text ↗ PubMed ↗
- Anhedonia and Depressive Disorders Serretti (2023) Full text ↗ PubMed ↗
- Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression Ling et al. (2022) Full text ↗ PubMed ↗
- Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics Aleksandrova et al. (2021) Full text ↗ PubMed ↗
- Ketamine for depression Jelen et al. (2021) PubMed ↗
- Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status Zarate et al. (2021) Full text ↗ PubMed ↗
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Kasper et al. (2021) PubMed ↗
Community
Log in to rate and share your notes.
No contributions yet.